Twist Bio CEO Sees Triple-Digit AI Order Growth After $300M Raise
TWST has more than doubled off its 52-week low of $23.3.
Summary
CEO Emily Leproust forecasts triple-digit percent order growth in fiscal 2027, driven by surging AI-driven drug discovery demand. This follows the upsized $300M offering priced at $96 per share last week, which closed around Aug 6. The offering funds R&D and manufacturing to capture an expanding opportunity funnel. The combination of fresh capital and a bullish demand outlook strengthens the growth narrative, though execution risk remains.
At the time of this announcement, TWST was trading at $118.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3B. The 52-week trading range was $23.30 to $118.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.